Literature DB >> 11207511

Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.

K R Herrlinger1, M K Noftz, K Fellermann, K Schmidt, J Steinhoff, E F Stange.   

Abstract

BACKGROUND: Conflicting data exist about proteinuria in inflammatory bowel diseases. It is still unclear whether the occurrence of proteinuria in inflammatory bowel disease patients is an extra-intestinal manifestation of disease or the result of adverse effects to medication, especially to aminosalicylates (ASA).
METHODS: A total of 95 patients (51 with Crohn's disease and 44 with ulcerative colitis) were enrolled in the study. Disease activity was assessed by Crohn's Disease Activity Index (CDAI) or the Truelove index, respectively. Urine was collected over 24 h and protein excretion of specific marker proteins for tubular (alpha 1-microglobulin-alpha 1-MG) and glomerular (albumin-Alb, Immunoglobulin G-IgG) dysfunction was measured using a highly sensitive immunoluminometric assay.
RESULTS: Out of 51 Crohn's disease patients, 20 showed elevated urinary alpha 1-MG. The amount of alpha 1-MGuria was strongly correlated to the CDAI (r=0.6, P < 0.001). Only four Crohn's disease patients showed slightly elevated values for glomerular proteins in urine. Similar results were obtained for ulcerative colitis: whereas only two ulcerative colitis patients showed albuminuria, tubular proteinuria was detected in 28 out of 44 ulcerative colitis patients. Proteinuria was strongly dependent on disease activity (P < 0.01) but was not related to ASA treatment.
CONCLUSIONS: Proteinuria of tubular marker proteins occurs in the majority of inflammatory bowel disease patients and is related to disease activity rather than to ASA treatment. Tubular proteinuria seems to reflect a renal extra-intestinal manifestation of inflammatory bowel disease and may serve as a new relevant marker of disease activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207511     DOI: 10.1046/j.1365-2036.2001.00940.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

1.  Morphea presenting as widespread oedema.

Authors:  Hamish Dobbie; John Lanham; Robert Unwin
Journal:  J R Soc Med       Date:  2002-09       Impact factor: 5.344

Review 2.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

Review 3.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 4.  Tubulointerstitial nephritis: diagnosis, treatment, and monitoring.

Authors:  Emily Joyce; Paulina Glasner; Sarangarajan Ranganathan; Agnieszka Swiatecka-Urban
Journal:  Pediatr Nephrol       Date:  2016-05-07       Impact factor: 3.714

5.  Acute interstitial nephritis associated with ulcerative colitis.

Authors:  Hirobumi Tokuyama; Shu Wakino; Konosuke Konishi; Akinori Hashiguchi; Koichi Hayashi; Hiroshi Itoh
Journal:  Clin Exp Nephrol       Date:  2010-05-25       Impact factor: 2.801

6.  Netrin-1 regulates colon-kidney cross talk through suppression of IL-6 function in a mouse model of DSS-colitis.

Authors:  Punithavathi Ranganathan; Calpurnia Jayakumar; Manicassamy Santhakumar; Ganesan Ramesh
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-27

7.  CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation.

Authors:  Punithavathi Ranganathan; Calpurnia Jayakumar; Santhakumar Manicassamy; Ganesan Ramesh
Journal:  Am J Physiol Renal Physiol       Date:  2013-08-28

8.  The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.

Authors:  Josephine M Ambruzs; Patrick D Walker; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

9.  Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?

Authors:  Androniki C Poulou; Konstantinos E Goumas; Dimitrios C Dandakis; Ioannis Tyrmpas; Maria Panagiotaki; Androniki Georgouli; Dimitrios C Soutos; Athanasios Archimandritis
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

10.  No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.

Authors:  Carsten Dehmer; Roland Greinwald; Juergen Löffler; Wolfgang Grotz; Lothar Wolf; Hans-Burkhardt Hagmann; Werner Schneider; Wolfgang Kreisel
Journal:  Int J Colorectal Dis       Date:  2003-02-08       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.